Replies to post #241437 on Biotech Values

[DewDiligence]

BMY 1Q22 results:

PR:
https://news.bms.com/news/corporate-financial/2022/Bristol-Myers-Squibb-Reports-First-Quarter-Financial-Results-for-2022/default.aspx

CC slides:
https://s21.q4cdn.com/104148044/files/doc_presentations/2022/BMY-2022-Q1-Results-Investor-Presentation.pdf

2022 non-GAAP EPS was lowered by $0.21 due to an FASB accounting change regarding in-process R&D (i.e. accounting for acquisitions). The updated range for 2022 non-GAP EPS (unchanged other than the item described above) is $7.44-7.74.